about
Breast metastases from oligodendroglioma: an unusual extraneural spread in two young women and a review of the literature.A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.Malignant pleural mesothelioma: current treatments and emerging drugs.Translational therapies for malignant pleural mesothelioma.Will antiangiogenic agents be a future for mesothelioma therapy?Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).Role of taxanes in pancreatic cancer.Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer.Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.Unity is strength: one, two, or more drugs against advanced pancreatic cancer?
P50
Q30662005-BFE64D53-DC5C-4DA2-A2BC-4B6A41BEFB7DQ33395577-19564BE0-A922-45AD-976C-20E2030B8E3EQ33409415-EF0B6828-C56F-426F-A655-046ACF8E1DCBQ33428348-0C47C210-47F9-42AA-8DE2-537DF52CD3F1Q33428382-9DB41466-D2B2-45B1-8F21-D8673DD77310Q33555296-FBDBE7E1-4CA0-4F49-8951-D9ADE04992EBQ33960866-13A7332E-6E84-48A9-A4BC-E2E913FA8F71Q37529848-5C1180B8-5B7B-4281-B43F-FCD3F68AAB1AQ37734455-AF1F88E6-E25F-416C-830C-5E5A66CDEB8DQ37772529-00B30ADB-97BE-40C6-A972-5F85C37D8993Q40352514-0308B7F4-20BA-4543-B3BA-1EEEA8FDE6AAQ42323567-F9175168-83D9-4CBC-9BA9-6F4AE8B9686EQ42525415-38224E00-404E-4C4D-9596-688DD68FF140Q46561847-6D21017E-D8D6-4FE2-9356-0CCB25CA75E3Q53314142-73BB680A-F733-4E04-954D-714212A82C5EQ61286871-CA84C4DC-4C98-4813-B266-A22D2F658618
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carmen Belli
@ast
Carmen Belli
@en
Carmen Belli
@es
Carmen Belli
@nl
Carmen Belli
@sl
type
label
Carmen Belli
@ast
Carmen Belli
@en
Carmen Belli
@es
Carmen Belli
@nl
Carmen Belli
@sl
prefLabel
Carmen Belli
@ast
Carmen Belli
@en
Carmen Belli
@es
Carmen Belli
@nl
Carmen Belli
@sl
P106
P21
P31
P496
0000-0001-7067-7496